분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-11-06 23:08:16 , Hit : 2169
 Experimental Hepatitis C Drug Shows Promise for Preventing Recurrence in Liver Transplant Patients


Oct. 31, 2013 — New drug therapies offer promise to some hepatitis C sufferers whose transplanted livers are threatened by a recurrence of the disease, including some patients who have had no treatment options.


--------------------------------------------------------------------------------

Share This:
The encouraging findings are contained in two new studies by a collaboration of researchers across the U.S. -- as well as in Spain and New Zealand -- including Dilip Moonka, M.D., medical director of Liver Transplant at Henry Ford Hospital.

Both studies are being presented at the annual meeting of the American Association for the Study of Liver Diseases being held in Washington, DC, Nov. 1-5.

Both studies focused on the experimental anti-viral drug sofosbuvir, a direct-acting oral medication that may take the place of injectable interferon, which causes severe side effects in some patients.

The U.S. Food and Drug Administration is expected to decide in early December whether to approve its use for treating hepatitis C. Last week, the Antiviral Drugs Advisory Committee of the FDA voted unanimously in support of approval for sofosbuvir-based therapies for the treatment of chronic hepatitis C.

Chronic hepatitis C, which afflicts an estimated 3 million people in the U.S. alone, is a blood-borne viral disease that leads to scarring and deterioration of the liver. It is particularly insidious because patients usually don't develop symptoms until the scarring -- or cirrhosis -- is well underway.

Sofosbuvir, which belongs to a class of drugs known as nucleotide analogue polymerase inhibitors, acts at the molecular level by interfering with the RNA of the hepatitis C virus.

In the first newly released study, researchers tested it as an alternative to interferon, a naturally occurring protein that plays a role in fighting viral infections, but commonly produces a range of serious side effects.

The researchers used it in combination with ribavirin, which also inhibits the hepatitis C virus by interfering with its RNA to stem the replication of the virus and slow the progression of the disease. They sought to test the drug combination's effectiveness in preventing recurrence of hepatitis C in liver transplant recipients.

A total of 61 chronic hepatitis C patients with liver cancer were enrolled in the study and given both sofosbuvir and ribavirin daily for up to 48 weeks before liver transplant. All of the patients had well-compensated cirrhosis, meaning their bodies were still functioning without too much trouble despite liver scarring. The researchers found that the new drug combination was both safe and effective in such patients and prevented post-transplant recurrence of the hepatitis C virus in more than 60 percent of them.

In the second newly released study, researchers focused on liver transplant recipients whose severe hepatitis C recurred after surgery and who either couldn't tolerate or didn't respond to approved antiviral therapies -- leaving them with no other effective treatment options. In such cases, experimental drugs can sometimes be tested under "compassionate use" protocols.

The researchers reported that as of April, 115 patients were approved for compassionate use of sofosbuvir combined with ribavirin and/or the anti-viral drug peginterferon. At the time of their report, 63 had started treatment.

After several weeks of treatment and study, the researchers concluded that patients with severe recurrence of hepatitis C after receiving transplanted livers were able to tolerate the drug regimen, which produced strong anti-viral effects. They reported "notable clinical improvements and/or disease stabilization in a majority of the patients."


Henry Ford Health System (2013, October 31). Experimental hepatitis C drug shows promise for preventing recurrence in liver transplant patients. ScienceDaily. Retrieved November 6, 2013, from http://www.sciencedaily.com­ /releases/2013/10/131031124620.htm







787   Un-junking junk DNA  이성욱 2013/11/15 1875
786   간염 발병시 면역계가 간 손상을 유발하는 기전  이성욱 2013/11/12 2062
785   젊음의 샘 유전자가 성체의 조직 손상을 치유  이성욱 2013/11/11 1944
784   CRISPR Madness  이성욱 2013/11/10 2204
783   RNA Controls Splicing During Gene Expression, Further Evidence of 'RNA World' Origin in Modern Life  이성욱 2013/11/07 2351
  Experimental Hepatitis C Drug Shows Promise for Preventing Recurrence in Liver Transplant Patients  이성욱 2013/11/06 2169
781   Scientists revolutionize the creation of genetically altered mice to model human disease  이성욱 2013/10/30 2577
780   유방암 발병 위험을 둘러싼 뜨거운 논란: BRCA vs BROCA  이성욱 2013/10/30 2375
779   거세 저항성 전립선 종양을 증식시키는 논코딩  이성욱 2013/08/23 2708
778   First Interferon-Free HCV Regimen Gets Unanimously Positive Vote  이성욱 2013/10/28 2273
777   암 전이와 싸우는 작은 조각의 유전 물질-마이크로 알앤에이  이성욱 2013/10/21 2218
776   감염위험을 증가시키는 HIV 백신  이성욱 2013/10/21 2229
775   형광성 항생제를 이용한 감염지점 파악방법  이성욱 2013/10/17 2110
774   대한민국 간암·간경화 원인은 70%가 B형, 15%가 C형 간염  이성욱 2013/10/14 2853
773   암 게놈 아틀라스 프로젝트- 치명적인 뇌종양의 비밀을 밝히다!!  이성욱 2013/10/14 2289
772   이제 미리 초기 간암 전구세포 확인  이성욱 2013/10/14 2349
771   포유류의 선천성 항 바이러스 파워 발견  이성욱 2013/10/14 2272
770   J&J's Janssen Buys Rights to Hepatitis C Compound from GSK  이성욱 2013/10/11 2155
769   제약업계 새 먹거리 ‘바이오베터’…미래 시장 두고 바이오시밀러와 한판  이성욱 2013/10/09 2873
768    3 Win Joint Nobel Prize in Medicine  이성욱 2013/10/08 2325

[이전 10개] [1]..[21][22][23][24] 25 [26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2023 Zeroboard / skin by ROBIN